Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Direct Meds vs Spry

Direct Meds
Graded #19

Higher grade

vs+25.799999999999997
Spry
Graded #408

Lower grade

The verdict

Direct Meds takes it — 82.6/100 to 56.8/100.

Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueDirect Meds +31
85
54
Dose & formulationDirect Meds +24
88
64
Clinical oversightDirect Meds +25
80
55
Labs & monitoringDirect Meds +26
78
52
FulfillmentDirect Meds +19
80
61
Contract termsDirect Meds +25
80
55
Direct Meds · left barSpry · right bar

The numbers

MetricDirect MedsSpry
WeighScore82.6/10056.8/100
GradeB−C
Scorecard rank#19#408
Semaglutide$179/mo$199/mo (starting dose, compounded)
Tirzepatide$224/mo$299/mo (starting dose, compounded)
CoverageNot publicly listedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Direct Meds

Graded #19 · B−

Strengths

  • Rare oral/sublingual option in addition to injectable
  • All-inclusive pricing with no separate membership fee
  • Both molecules — semaglutide and tirzepatide
  • Intro promotional pricing near $147

Where it loses points

  • Compounded only — not FDA-approved
  • Pricing is company-stated, not independently live-verified
  • Newer and somewhat ambiguous (operates across multiple domains)
  • States served are not disclosed
Spry

Graded #408 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard